File photo


Drug Regulatory Authority of Pakistan will conduct a market surveillance to check the sale of spurious, fake, counterfeit and substandard drugs in the country.

According to DRAP, the step is being taken for provision of quality assured, safe, effective and affordable medicine to citizens.     

The DRAP teams will also provide guidance to industry and pharma trade for improving distribution, sales and dispensing of therapeutic goods.    

The campaign will also include drive for improving drug quality through integrated and systematic regulatory compliance for manufacturing facilities.


Third-party Ads